Sonorous Neurovascular Gains FDA Approval for Pioneering Pulsatile Tinnitus Treatment in the U.S.

Sonorous Neurovascular's Groundbreaking FDA Approval

Sonorous Neurovascular, a clinical-stage medical device company, has made waves recently with an important announcement: the FDA has granted them the Investigational Device Exemption (IDE) on October 2, 2026. This approval paves the way for the initiation of B-SILENT 2, a pivotal trial in the United States focusing on their innovative BosSTENT™. This first-of-its-kind device, designed specifically for the venous sinuses, aims to treat pulsatile tinnitus resulting from venous sinus stenosis.

Pulsatile tinnitus, a condition characterized by rhythmic sounds that synchronize with a person's heartbeat, can significantly impair quality of life. In the ARISE II study published in the American Journal of Neuroradiology earlier this year, a considerable number of patients reported serious issues such as debilitating anxiety, major depression, and even thoughts of self-harm. The common underlying cause of pulsatile tinnitus in many of these cases is venous sinus stenosis, making the development of targeted therapies a critical need in the medical community.

The BosSTENT™ stands out as a braided, self-expanding stent, ensuring optimized integration with cerebral venous anatomy. This signifies a focused approach to treating the condition, rather than relying on generalized devices designed for unrelated medical issues.

Joel M. Harris, CEO of Sonorous Neurovascular, emphasized that the FDA IDE approval represents not just a milestone for their company but also a significant step forward in addressing the treatment challenges patients suffering from pulsatile tinnitus face. With the B-SILENT 2 trial, which complements the company's ongoing international B-SILENT program, Sonorous is on a trajectory to generate essential clinical evidence aimed at helping patients in both the United States and major international markets.

Dr. Emanuele Orru, Co-Principal Investigator of the B-SILENT 2 trial, highlighted the need for evidence-based treatment decisions, which lays the groundwork for establishing a robust framework for patient selection and treatment methods. This study serves to evaluate the BosSTENT™ within a new standard dedicated to the unique challenges associated with pulsatile tinnitus.

The significance of this advancement cannot be overstated. The B-SILENT 2 trial is not limited to the U.S. alone; internationally, the B-SILENT study (NCT07070089) is also gaining momentum, currently enrolling participants in various centers across France and Canada. This strategic effort supports the objective of achieving CE Mark certification for the BosSTENT™.

Notably, this FDA IDE achievement comes on the heels of two other significant milestones for Sonorous Neurovascular in just eight months: receiving Breakthrough Device Designation for the BosSTENT™ in February 2026 and obtaining 510(k) clearance for their BosCATH™ Support Catheter in April 2026. This indicates the rapid advancements within Sonorous's innovative platform for cerebral venous disease treatment.

Although the BosSTENT™ awaits commercialization within the United States, its clinical applications continue to unfold globally, showcasing Sonorous Neurovascular's commitment to alleviating the suffering of those burdened by pulsatile tinnitus. Harris concluded, "This milestone pushes our vision of establishing dedicated treatments for cerebral venous diseases further into reality."

The BosSTENT™ remains investigational and is not available for commercial sale according to U.S. law, although it marks a promising future for patients plagued by pulsatile tinnitus.

For those unfamiliar with pulsatile tinnitus, it is essential to note that the condition generates a sound that is distinctly rhythmic, often referred to as a whooshing or pulsing noise. Unlike conventional tinnitus, its origin can frequently be traced back to vascular abnormalities, making it a unique challenge in clinical practices.

In conclusion, Sonorous Neurovascular is on the brink of revolutionizing the treatment approach for pulsatile tinnitus with its innovative BosSTENT™ and the newly approved B-SILENT 2 trial, showcasing the potential to change countless lives.